Login to Your Account



Blueprint tops expectations, re-writes SM pivotal pathway with BLU-285

By Marie Power
News Editor

Monday, December 11, 2017

ATLANTA – Shares of Blueprint Medicines Corp. popped 25 percent at Monday's opening bell, closing the day at $88.32 for a gain of $16.46, after the company wowed participants at the American Society of Hematology annual meeting with a presentation of data from the ongoing phase I trial of BLU-285 – now named avapritinib – in advanced systemic mastocytosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription